Synthetic cannabinoids use in a sample of opioid-use disorder patients
Alías Ferri, María (Institut Hospital del Mar d'Investigacions Mèdiques)
Pellegrini, Manuela (National Centre on Istituto Superiore di Sanità (Itàlia))
Marchei, Emilia (Istituto Superiore di Sanità (Itàlia))
Pacifici, Roberta (Istituto Superiore di Sanità (Itàlia))
Rotolo, Maria Concetta (Istituto Superiore di Sanità (Itàlia))
Pichini, Simona (National Istituto Superiore di Sanità (Itàlia))
Pérez-Mañá, Clara (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Papaseit, Esther (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Muga, Roberto (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Fonseca, Francina 1972- (Institut Hospital del Mar d'Investigacions Mèdiques)
Farre, Magi (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Torrens, Marta (Institut Hospital del Mar d'Investigacions Mèdiques)
Universitat Autònoma de Barcelona

Fecha:	2022
Resumen:	Cannabis is the most widely consumed illegal drug in the world and synthetic cannabinoids are increasingly gaining popularity and replacing traditional cannabis. These substances are a type of new psychoactive substance that mimics the cannabis effects but often are more severe. Since, people with opioids use disorder use widely cannabis, they are a population vulnerable to use synthetic cannabinoids. In addition, these substances are not detected by the standard test used in the clinical practice and drug-checking is more common in recreational settings. A cross-sectional study with samples of 301 opioid use disorder individuals was carried out at the addiction care services from Barcelona and Badalona. Urinalysis was performed by high-sensitivity gas chromatography-mass spectrometry (GC-MS) and ultra-high-performance liquid chromatography-high -resolution mass spectrometry (UHPLC-HRMS). Any synthetic cannabinoid was detected in 4. 3% of the individuals and in 23% of these samples two or more synthetic cannabinoids were detected. Among the 8 different synthetic cannabinoids detected, most common were JWH-032 and JWH-122. Natural cannabis was detected in the 18. 6% of the samples and only in the 0. 7% of them THC was identified. Several different synthetic cannabinoids were detected and a non-negligible percentage of natural cannabis was detected among our sample. Our results suggest that the use of synthetic cannabinoids may be related to the avoidance of detection. In the absence of methods for the detection of these substances in clinical practice, there are insufficient data and knowledge making difficult to understand about this phenomenon among opioid use disorder population.
Ayudas:	Instituto de Salud Carlos III PI17/01962 Instituto de Salud Carlos III PI20/00804
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Cannabis ; New psychoactive substances ; Opioid use disorder ; Synthetic cannabinoid ; Urine sample analysis
Publicado en:	Frontiers in psychiatry, Vol. 13 (august 2022) , ISSN 1664-0640

DOI: 10.3389/fpsyt.2022.956120
PMID: 35990071

5 p, 154.0 KB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Artículos > Artículos de investigación
Artículos > Artículos publicados